瑞舒伐他汀联合非诺贝特对老年糖尿病视网膜病变患者血管内皮功能的影响

doi:10.6040/j.issn.1673-3770.0.2015.142

摘要/Abstract

摘要： 目的分析瑞舒伐他汀联合非诺贝特治疗老年糖尿病视网膜病变患者时,对血清单核细胞趋化因子-1(MCP-1)、基质金属蛋白酶-9(MMP-9)、血管内皮生长因子(VEGF)水平的影响。方法选择糖尿病视网膜病变患者140例,按入院先后顺序,以随机数字表法将患者分为瑞舒伐他汀组(单药组)和瑞舒伐他汀与非诺贝特联合治疗组(联合组)各70例。二组患者性别、年龄、体质量、血脂、血压及糖化血红蛋白水平差异无统计学意义(P>0.05)。单药组给予瑞舒伐他汀钙10 mg/d,联合组在单药组基础上给予非诺贝特胶囊100 mg/次,3次/d,观察时间为3个月。治疗前与治疗后晨空腹抽取肘静脉血,酶联免疫吸附法检测血清单核细胞趋化因子-1(MCP-1)、基质金属蛋白酶-9(MMP-9)及血管内皮生长因子(VEGF)水平的变化。结果单药组患者治疗后与治疗前比较, MCP-1[(2.59±0.38)比(3.23±0.61)μg/L,t=2.697]、MMP-9[(47.47±5.13)比(69.38±6.28)ng/L,t=2.868]、VEGF[(125.48±8.27)比(198.47±12.63)ng/L,t=2.846];联合组患者治疗后与治疗前比较, MCP-1[1.14±0.29)比(3.17±0.53)μg/L,t=3.217]、MMP-9[(34.18±4.29)比(71.05±7.36)ng/L,t=3.163]、VEGF[(87.39±10.27)比(195.28±11.49)ng/L,t=3.352],二组患者上述指标治疗后明显减少,差异有统计学意义(P<0.05)。其中,治疗后联合组MCP-1、MMP-9、VEGF水平较单纯组减少更为显著,差异有统计学意义(P<0.05)。结论瑞舒伐他汀钙与非诺贝特联合治疗有助于维持老年糖尿病视网膜病变患者血管内皮细胞功能稳定。

关键词: 瑞舒伐他汀钙, 糖尿病视网膜病变, 基质金属蛋白酶-9, 单核细胞趋化因子-1, 血管内皮生长因子

Abstract: Objective To investigate the effects of rosuvastatin combined with fenofibrate therapy on monocyte chemotactic factor-1 (MCP-1), matrix metalloproteinase-9 (MMP-9), and vascular endothelial growth factor (VEGF) in elderly diabetic patients with retinopathy. Methods A total of 140 cases with diabetic retinopathy admitted during Oct. 2012 and Oct. 2014 were randomly divided into rosuvastatin group (single drug group, n=70), and rosuvastatin and fenofibrate treatment group (combined group, n=70). The single drug group received rosuvastatin calcium 10 mg/d, while the combined group were given rosuvastatin calcium 10mg/d, and Fenofibrate Capsules 100 mg once for 3 times each day. The clinical baseline levels of sex, age, body weight index, blood lipid, blood pressure and andglycated hemoglobin in the two groups had no significant differences (P<0.05). The changes of MCP-1, MMP-9 and VEGF before and after treatment were compared. Results The levels of MCP-1, MMP-9 and VEGF in the single drug group were [(2.59±0.38) vs (3.23±0.61) μg/L,t=2.697], [(47.47±5.13) vs (69.38±6.28) ng/L, t=2.868], [(125.48±8.27) vs (198.47±12.63) ng/L, t=2.846], while the levels of MCP-1, MMP-9 and VEGF in the combined group were [(1.14±0.29) vs (3.17±0.53) μg/L, t=3.217], [(34.18±4.29) vs (71.05±7.36) ng/L, t=3.163], [(87.39±10.27) vs (195.28±11.49) ng/L, t=3.352], before and after treatment, respectively. The indexes in the two groups significantly reduced after treatment. The levels of MCP-1, MMP-9 and VEGF in combined group reduced more significantly than in the single drug group, and the difference was statistically significant (P<0.05). Conclusion Rosuvastatin calcium and fenofibrate treatment contributes to the stable endothelial function in elderly diabetic retinopathy patients.

Key words: Endothelial function, Matrix metalloproteinase-9, Vascular endothelial growth factor, Diabetic retinopathy, Monocyte hemotactic factor-1

中图分类号:

R774.1

李俊英. 瑞舒伐他汀联合非诺贝特对老年糖尿病视网膜病变患者血管内皮功能的影响[J]. 山东大学耳鼻喉眼学报, 2015, 29(5): 72-75.

LI Junying. Effects of rosuvastatin combined with fenofibrate therapy on vascular endothelial function retinopathy diabetic retinopathy patients[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(5): 72-75.

参考文献

[1] 郑志. 糖尿病视网膜病变临床防治:进展、挑战与展望[J]. 中华眼底病杂志, 2012, 28(3):209-212. ZHENG Zhi. Clinical prevention and treatment of diabetic retinopathy: progress, challenges and prospects[J]. Chin J Ocul Fundus Dis, 2012, 28(3):209-212.
[2] 王月欣, 陈松. 糖尿病视网膜病变神经损伤的发病机制和保护防治研究进展[J]. 中华眼底病杂志, 2014, 30(2):209-211. WANG Yuexin, CHEN Song. Research progress and protection of diabetic retinopathy in the pathogenesis[J]. Chin J Ocul Fundus Dis, 2014, 30(2):209-211.
[3] 朱鸿, 朱耀春, 胡海林, 等. 糖尿病视网膜病变相关临床和生物化学指标的检测和预警意义[J]. 中华眼底病杂志, 2012, 28(3):219-223. ZHU Hong, ZHU Yaochun, HU Hailin, et al. Detection and early warning significance of clinical and biochemical parameters in diabetic retinopathy[J]. Chin J Ocul Fundus Dis, 2012, 28(3): 219-223.
[4] 谢安明, 王雅君, 崔丽君. 血管内皮祖细胞与VEGF对增生性糖尿病视网膜病变新生血管形成的影响[J]. 西安交通大学学报:医学版, 2013, 34(2):233-235. XIE Anming, WAGN Yajun, CUI Lijun, et al. Effect of vascular endothelial progenitor cells and VEGF on angiogenesis in proliferative diabetic retinopathy[J]. J Xi'an Jiao Tong University: Med Edition, 2013, 34(2): 233-235.
[5] 李建军, 糖尿病视网膜病变诊断及治疗建议[J]. 眼科, 2005, 14(4): 24-26. LI Jianjun. Diagnosis and treatment of diabetic retinopathy[J]. Ophthalmol, 2005, 14(4):24-26.
[6] 杨继玲, 邵毅, 裴重刚. 调脂药治疗糖尿病视网膜病变的研究进展[J]. 中华眼底病杂志, 2014, 30(2):216-218. YANG Jiling, SHAO Yi, PEI Chonggang. Progress in the treatment of diabetic retinopathy by lipid profile[J]. Chin J Ocul Fundus Dis, 2014, 30(2):216-218.
[7] 祝伟, 苏冠方, 王晨光, 等. 糖尿病视网膜病变的病理机制和新型药物研究进展[J]. 中国老年学杂志, 2013, 33(3): 1206-1209. ZHU Wei, SU Guanfang, WANG Chenguang, et al. Research progress of pathological mechanism and new drugs for diabetic retinopathy[J]. Chin J Gerontol, 2013, 33(3):1206-1209.
[8] Ceraldes P, Hiraoka-Yamamoto J, Matsumoto M, et al. Activation of PKC-dalta and SHP-1 by hyperglycemia causes cascular cell apoptosis and diabetic retinopathy[J]. Nat Med, 2009, 15(11):1298-1306.
[9] Kim J H, Yu Y S. Blockade of angiotensin II attenuates VEGF-mediated blood retinal barrier breakdown in diabetic retinopathy[J].J Cerebr Blood F Met, 2009, 29(3):621-628.
[10] Adamiec-Mroczek J, Oficjalska-Mlynczak J, Misiuk-Hojlo M. Proliferative diabetic retinopathy the influence of diabetes control on the activation of the intraocular molecule system[J]. Didbetes Res Clin Pract, 2009, 84(1):46-50.

相关文章 15

[1]	赵娟,焦万珍,赵博军. UWFSS-OCTA检测糖尿病视网膜病变微循环的变化[J]. 山东大学耳鼻喉眼学报, 2026, 40(2): 80-86.
[2]	朱明琼,李征,刘茹,田涛,彭婧利,吕倩怡,谭华霞. 基于OCT/OCTA的AI筛查系统在抗VEGF治疗糖尿病性黄斑水肿患者效果评价中的应用[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 68-73.
[3]	孙庆祝,沈健,陈星,吴雁冰,曾论. 代谢指标在预测糖尿病性黄斑水肿患者雷珠单抗疗效中的作用[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 74-81.
[4]	辛梦,纪芳,代春华,张靖,刘澍. 医用透明质酸钠与平衡盐溶液在微创玻璃体手术中对眼表保护的影响[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 58-65.
[5]	常威威,焦万珍,崔艳艳,赵杰,刘兆强,赵博军. 糖尿病性黄斑缺血的研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 130-136.
[6]	何静,雷春燕,张美霞. 糖化血红蛋白变异指数与糖尿病视网膜病变严重程度的相关性研究[J]. 山东大学耳鼻喉眼学报, 2024, 38(2): 34-40.
[7]	伦英俊,陈晨,高宏程,范清琳,邰仁清. TLR4/NF-κB通道在糖尿病视网膜病变中的作用[J]. 山东大学耳鼻喉眼学报, 2024, 38(2): 163-168.
[8]	王丽雪,曾毅,王丽欣,彭先兵. 浸润毕罗芬明胶海绵在功能性鼻内镜鼻窦手术后应用效果的临床观察[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 16-25.
[9]	徐恩沛,孙先勇. 渗出性年龄相关性黄斑变性并发视网膜色素上皮脱离的诊治进展[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 125-142.
[10]	唐慧新,李景景,邹红. 阈值下微脉冲激光光凝作用机制及临床应用[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 143-148.
[11]	刘通,林玮,冯萌,杨依,刘婷婷,张敏. 基于网络药理学分析小檗碱在免疫微环境中对糖尿病视网膜病变的作用及实验验证[J]. 山东大学耳鼻喉眼学报, 2023, 37(1): 94-104.
[12]	王露萍,寇芳柠,王皓,张灿伟,王艳玲,尤冉,吴伟珍. 视网膜下高反射物质在抗VEGF治疗nAMD患者中对视力预后的影响[J]. 山东大学耳鼻喉眼学报, 2022, 36(6): 101-105.
[13]	李曼冯雪,王艳玲. 眼缺血综合征与缺血性脑卒中相关性研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(5): 88-92.
[14]	王娇娇,李苗宋宗明. 糖尿病视网膜病变的机制和细胞模型研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(5): 93-99.
[15]	王惠, 王俊,孙乙,于腾飞,朱玉广, 朱艳. 玻璃体腔注射HGF-MSCs对糖尿病大鼠视网膜HGF表达的影响[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 72-77.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed